Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02414568 | Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin(PVAB) | completed | Phase 2 | 90 | The Lymphoma Academic Research OrganisationOTHER | 2 | Feb 21, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER |
| 1 |
| Feb 3, 2021 |
| clinicaltrials |
| NCT04373083 | Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma | withdrawn | Phase 2 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jan 15, 2021 | clinicaltrials |
| NCT01169636 | Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT02227433 | Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.(FIL_BVHD01) | completed | Phase 2 | 20 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT00670592 | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | completed | Phase 1 / Phase 2 | 111 | Novartis PharmaceuticalsINDUSTRY | 11 | Dec 17, 2020 | clinicaltrials |
| NCT03739606 | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 17, 2020 | clinicaltrials |
| NCT01121120 | Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients(TXA127-PBSC) | terminated | Phase 2 | 75 | Tarix PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03114683 | Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma(ORIENT-1) | completed | Phase 2 | 96 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Dec 7, 2020 | clinicaltrials |
| NCT04653649 | CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. | unknown | Phase 1 / Phase 2 | 30 | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT02321592 | GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma(GHSG-AFM13) | completed | Phase 2 | 23 | University of CologneOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT01075321 | Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 58 | Mayo ClinicOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT02991898 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | terminated | Phase 2 | 3 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT00478959 | Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 2 | 30 | University Health Network, TorontoOTHER | 0 | Sep 18, 2020 | clinicaltrials |
| NCT02505269 | Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma | completed | Phase 2 | 34 | Massachusetts General HospitalOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT04514081 | The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. | unknown | Phase 2 | 200 | Chinese PLA General HospitalOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT02875067 | Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 6 | NYU Langone HealthOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT04233294 | Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma | unknown | Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT04510610 | Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | unknown | Phase 2 / Phase 3 | 100 | Chinese PLA General HospitalOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT01921387 | Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 4, 2020 | clinicaltrials |
| NCT03474133 | Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)(BASALT) | unknown | Phase 2 | 80 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jul 21, 2020 | clinicaltrials |
| NCT01217229 | Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 20 | Daiichi SankyoINDUSTRY | 1 | Jun 30, 2020 | clinicaltrials |
| NCT03343652 | A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma(NB001) | completed | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT02003625 | Meloxicam vs Placebo for Mobilization | completed | Phase 2 | 31 | Massachusetts General HospitalOTHER | 1 | May 18, 2020 | clinicaltrials |
| NCT00967369 | Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment. | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 20, 2020 | clinicaltrials |
| NCT00566696 | Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | completed | Phase 2 | 73 | St. Jude Children's Research HospitalOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT00082888 | Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma | completed | Phase 2 | 93 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2020 | clinicaltrials |
| NCT02164500 | JAK-inhibition in Recurrent Classical Hodgkin Lymphoma(JeRiCHO) | completed | Phase 2 | 12 | University of CologneOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT00654732 | Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma | completed | Phase 2 | 58 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT00068718 | Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant | completed | Phase 1 / Phase 2 | 35 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 31, 2020 | clinicaltrials |
| NCT00096161 | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant | completed | Phase 2 | 36 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 31, 2020 | clinicaltrials |
| NCT00789776 | Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer | completed | Phase 1 / Phase 2 | 41 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT00005803 | Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma | completed | Phase 1 / Phase 2 | 76 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT00040846 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT03343665 | Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma(Nivo40) | completed | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT04239170 | Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma | unknown | Phase 2 | 84 | Peking UniversityOTHER | 1 | Jan 23, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT00343564 | A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 68 | CytokineticsINDUSTRY | 2 | Jan 13, 2020 | clinicaltrials |
| NCT00481871 | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies | completed | Phase 1 / Phase 2 | 119 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 7, 2020 | clinicaltrials |
| NCT01527045 | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 47 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00723099 | Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer | completed | Phase 2 | 73 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 27, 2019 | clinicaltrials |
| NCT00027820 | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | Phase 1 / Phase 2 | 106 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 20, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01251575 | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | completed | Phase 2 | 77 | Fred Hutchinson Cancer CenterOTHER | 2 | Dec 9, 2019 | clinicaltrials |
| NCT00185692 | Allogeneic Transplantation From Related Haploidentical Donors | completed | Phase 2 | 16 | Stanford UniversityOTHER | 1 | Dec 4, 2019 | clinicaltrials |
| NCT03527628 | OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy((Optimist)) | unknown | Phase 2 | 220 | King Abdullah International Medical Research CenterOTHER | 1 | Nov 18, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Feb 21, 2021source: clinicaltrials